Clayton Utz and Fasken Martineau DuMoulin LLP acted for Anglo Pacific Group plc on the acquisition. South32 Ltd has entered into a binding agreement for the...
You must be a Standard 1 Year member to access this content.
Fasken Martineau DuMoulin LLP advised the sole agent and sole bookrunner. On July 4, 2022, Algernon Pharmaceuticals Inc. (CNSX:AGN) announced the closing of its previously announced marketed...
You must be a Standard 1 Year member to access this content.
Fasken Martineau DuMoulin LLP advised Research Capital Corporation on the matter. GeneTether Therapeutics Inc. (CSE: GTTX), an innovative genetic medicines company, completed an initial public offering of...
You must be a Standard 1 Year member to access this content.
Fasken Martineau DuMoulin LLP advised Elemental Royalties Corp. on the matter. On April 1, 2022, Elemental Royalties Corp. (CVE:ELE) (OTCQX: ELEMF), a gold-focused royalty company, closed its previously...
You must be a Standard 1 Year member to access this content.
Middlefield Limited, the manager of the Fund, was advised by Fasken Martineau DuMoulin LLP. On August 30, 2021 Real Estate & E-Commerce Split Corp. (TSX: RS and...
You must be a Standard 1 Year member to access this content.
Fasken advised the sole bookrunner. On June 29, 2021, Valeo Pharma Inc., a Canadian pharmaceutical company, announced the closing of its “bought deal” short form prospectus...
You must be a Standard 1 Year member to access this content.
Fasken acted for Middlefield Limited, the manager of the Partnership. On April 9, 2021, MRF 2021 Resource Limited Partnership completed the final closing of the initial public...
You must be a Standard 1 Year member to access this content.
Fasken advised Middlefield Limited, the manager of the Fund. On April 27, 2021 E Split Corp. (TSX: ENS and ENS.PR.A) completed an overnight public offering of...
You must be a Standard 1 Year member to access this content.
